Efficacy outcomes:
The primary efficacy outcomes were composite of kidney failure: “a sustained decrease of at least 40% in the eGFR from baseline over a period of at least 4 weeks, or death from renal causes. Kidney failure was defined as end-stage kidney disease or an eGFR of less than 15 ml per minute per 1.73 m2; end-stage kidney disease was defined as the initiation of long-term dialysis (for ≥90 days) or kidney transplantation”, composite of death from cardiovascular causes: nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Other secondary outcomes were death from any cause, hospitalization for any cause, the change in the urinary albumin-to-creatinine ratio from baseline to month 4, and a composite of kidney failure, a sustained decrease of at least 57% in the eGFR from baseline (equivalent to a doubling of the serum creatinine level) maintained for at least 4 weeks, or death from renal causes.